Literature DB >> 12853461

Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.

Hélène Pelicano1, Li Feng, Yan Zhou, Jennifer S Carew, Elizabeth O Hileman, William Plunkett, Michael J Keating, Peng Huang.   

Abstract

Cancer cells are under intrinsic increased oxidative stress and vulnerable to free radical-induced apoptosis. Here, we report a strategy to hinder mitochondrial electron transport and increase superoxide O2. radical generation in human leukemia cells as a novel mechanism to enhance apoptosis induced by anticancer agents. This strategy was first tested in a proof-of-principle study using rotenone, a specific inhibitor of mitochondrial electron transport complex I. Partial inhibition of mitochondrial respiration enhances electron leakage from the transport chain, leading to an increase in O2. generation and sensitization of the leukemia cells to anticancer agents whose action involve free radical generation. Using leukemia cells with genetic alterations in mitochondrial DNA and biochemical approaches, we further demonstrated that As2O3, a clinically active anti-leukemia agent, inhibits mitochondrial respiratory function, increases free radical generation, and enhances the activity of another O2.-generating agent against cultured leukemia cells and primary leukemia cells isolated from patients. Our study shows that interfering mitochondrial respiration is a novel mechanism by which As2O3 increases generation of free radicals. This novel mechanism of action provides a biochemical basis for developing new drug combination strategies using As2O3 to enhance the activity of anticancer agents by promoting generation of free radicals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853461     DOI: 10.1074/jbc.M301546200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  133 in total

1.  Fully functionalized small-molecule probes for integrated phenotypic screening and target identification.

Authors:  Justin S Cisar; Benjamin F Cravatt
Journal:  J Am Chem Soc       Date:  2012-06-13       Impact factor: 15.419

2.  Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells.

Authors:  Melba C Jaramillo; Margaret M Briehl; Ines Batinic-Haberle; Margaret E Tome
Journal:  Free Radic Biol Med       Date:  2015-02-26       Impact factor: 7.376

3.  The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Authors:  Alejandro G Levy; Peter E Zage; Lauren J Akers; Maurizio L Ghisoli; Zhao Chen; Wendy Fang; Sankaranarayanan Kannan; Timothy Graham; Lizhi Zeng; Anna R Franklin; Peng Huang; Patrick A Zweidler-McKay
Journal:  Invest New Drugs       Date:  2010-10-05       Impact factor: 3.850

4.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

5.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

Authors:  Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Journal:  Leuk Res       Date:  2007-01-22       Impact factor: 3.156

6.  Therapeutic Potential of Arsenic Trioxide (ATO) in Treatment of Hepatocellular Carcinoma: Role of Oxidative Stress in ATO-Induced Apoptosis.

Authors:  Erika B Dugo; Clement G Yedjou; Jacqueline J Stevens; Paul B Tchounwou
Journal:  Ann Clin Pathol       Date:  2017-01-04

7.  Enhanced singlet oxygen production by photodynamic therapy and a novel method for its intracellular measurement.

Authors:  Sandra L Pena Luengas; Gustavo Horacio Marin; Kevin Aviles; Ricardo Cruz Acuña; Gustavo Roque; Felipe Rodríguez Nieto; Francisco Sanchez; Adrián Tarditi; Luis Rivera; Eduardo Mansilla
Journal:  Cancer Biother Radiopharm       Date:  2014-12       Impact factor: 3.099

Review 8.  Targeting cancer cell mitochondria as a therapeutic approach.

Authors:  Shijun Wen; Daqian Zhu; Peng Huang
Journal:  Future Med Chem       Date:  2013-01       Impact factor: 3.808

Review 9.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

10.  ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.

Authors:  Xiaohua Peng; Varsha Gandhi
Journal:  Ther Deliv       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.